Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF - Get Free Report)'s stock price reached a new 52-week low during trading on Friday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on RCDTF. Barclays raised shares of Recordati Industria Chimica e Farmaceutica to a "strong sell" rating in a research report on Tuesday. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a "hold" rating in a research report on Monday, October 7th.
View Our Latest Research Report on RCDTF
Recordati Industria Chimica e Farmaceutica Stock Performance
The firm's 50 day moving average price is $52.25 and its 200-day moving average price is $51.88. The firm has a market cap of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95.
Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The company had revenue of $622.00 million for the quarter.
About Recordati Industria Chimica e Farmaceutica
(
Get Free Report)
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recordati Industria Chimica e Farmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recordati Industria Chimica e Farmaceutica wasn't on the list.
While Recordati Industria Chimica e Farmaceutica currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
